Source link : https://www.newshealth.biz/health-news/tusa-rav-not-better-than-docetaxel-for-nsclc/
SAN DIEGO — The novel antibody-drug conjugate tusamitamab ravtansine (tusa rav, Sanofi) did not demonstrate greater efficacy than docetaxel in treating advanced nonsquamous non–small cell lung cancer (NSCLC), according to the final results of a study. These findings, which were presented at the World Conference on Lung Cancer (WCLC) 2024 on September 9, led to […]
Author : News Health
Publish date : 2024-09-12 14:13:21
Copyright for syndicated content belongs to the linked Source.
Categories